New depression pill shows promise in clinical trial

NCT ID NCT03870776

Completed Symptom relief Sponsor: Mapreg Source: ClinicalTrials.gov ↗

First seen Apr 01, 2026 · Last updated May 13, 2026 · Updated 6 times

Summary

This study tested an experimental daily pill called MAP4343 in 126 adults whose depression did not improve with standard antidepressants. The goal was to see if the drug could reduce depressive symptoms over 6 weeks. The trial was a Phase 2 study, meaning it was an early test of effectiveness and safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

APHP Hôpital La Pitié Salpétrière - Prinicipal investigator center

Paris, 75013, France
CHD Vendée

La Roche-sur-Yon, 85000, France
CHRU Tours

Tours, 37000, France
CHU Angers

Angers, 49900, France
CHU Besançon

Besançon, 25000, France
CHU Henri Laborit

Poitiers, 86000, France
CHU Nantes

Nantes, 44000, France
Cabinet Médical Ambroise Paré

Élancourt, 78990, France
Hôpital Fontan 1

Lille, 59000, France
Hôpital Ste Anne

Paris, 75014, France

Conditions

Explore the condition pages connected to this study.

DEPRESSION